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INTRODUCTION Investigations
Short course chemotherapy (SCC) is now widely Tuberculin test with 1TU (PPD Batch. RT 23
accepted as the treatment of choice for adult pulmo- with tween 80) was done on admission and read
nary tuberculosis but there is relatively little infor- after 2 or 3 (occasionally 4) days. Urine tests for
mation on the value of the same in childhood tuber-
culosis, in particular tuberculous meningitis. The
results of the earlier 3 chemotherapy studies on tu-
berculous meningitis in children, conducted by the
Tuberculosis Research Centre, Chennai1 showed
that the mortality was very high. Hence, the Centre
undertook the short course chemotherapy study
where patients were treated with more intensive
regimens, with 5 drugs in the initial phase. followed
by two bactericidal drugs during the follow up
phase. This paper presents the results of the above
study.
Plan and conduct of the study
A total of 215 patients, aged between 1 and 12
years, who had not received more than 4 weeks of
previous anti-tuberculosis chemotherapy, bad no
evidence of renal or liver disease and bad no optic
atrophy or pallor of optic discs, were admitted to
the study.
Criteria for diagnosis
The diagnosis was based on clinical symptoms
and signs like fever, vomiting, irritability. apathy,
anorexia, constipation, refusal to play, in the initial
stages followed by presence of meningeal signs and
impaired consciousness. coma and widespread
paralysis. The cerebrospinal fluid (CSF) findings
were also taken into consideration. A CSF protein
value of more than 40 mg% plus cell count more
than 10/cmm (predominantly lymphocytes) was
taken as confirmatory.
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Acetyl Isoniazid, bile salts, bile pigments,
urobilinogen, albumin and deposits were done on
admission, at 1 and 2 months and, thereafter, tests
for albumin and Acetyl Isoniazid were done every
month. Anteroposterior chest radiographs were
taken on admission and at the end of treatment.
Routine haematological investigations, including
liver function tests, urea and creatinine were done
on admission, at 1 and 2 months and end of
treatment. Biochemical, cytological and
bacteriological examinations of the CSF were done
on admission and once a month subsequently till
the results became normal.
On admission, the patients were classified into 3
stages according to severity, using the classification
suggested by the British Medical Research
Council2 :
Stage I : Patients were conscious and had mainly
non-specific symptoms, with or without
signs of meningeal irritation, but no
focal neurological signs. Diagnosis was
established mainly on CSF findings.
Stage II : Patients were mentally confused and/or
had neurological signs.
Stage III : Patients were comatose and had gross
neurological signs.
Patients found suitable were randomly allocated,
after stratification according to the stage of the
disease. in equal proportion to the two regimens :
Regimen I : 2S7H7E7R3Z3/7R2H2
Streptomycin, Isoniazid and Ethambutol daily
supplemented by Rifampicin and Pyrazinamide
thrice a week for 2 months followed by Rifampicin
and Isoniazid twice a week for the next 7 months.
Regimen II : 2S7H7E7R2Z2/7R2H2
Regimen II was the same as regimen I except
that Rifampicin and Pyrazinamide were given twice
instead of thrice a week during the first 2 months.
Dosage of Drugs
Streptomycin was given in a dosage of 40 mg/kg
body weight. Isoniazid 12 mg/kg and Ethambutol
20 mg/kg for 2 weeks, followed by 15 mg/kg for
the next 6 weeks. Pyrazinamide was administered in
a dose of 30 mg/kg in the thrice weekly regimen
and 40 mg/kg in the twice weekly regimen.
Rifampicin was given in a dose of 12 mg/kg. In
addition to the anti-tuberculosis drugs, the patients
received supportive therapy like I.V. fluids, anti-
oedema measures, anti-convulsants and vitamins.
Steroids were administered to all the patients.
Seriously ill patients were given dexamethasone by
the intra-muscular route in a dosage of 2-3 mg
every 6-8 hours for the first 3-4 days followed by
oral Prednisolone in a dosage of 1-2 mg/kg.
General Management
Patients were hospitalised for a minimum period
of 2 months or more, if necessary. However, those
who showed very good improvement were
discharged at request before completing the
intensive phase of two months treatment (mostly
stage I patients) and asked to attend daily until they
completed 2 months of treatment. After two
months, the patients attended twice or once a week
(or once in 15 days if they lived outside Chennai
city) to collect drugs. They were given the drugs
under supervision on the days they attended. The
progress was assessed by monthly examination.
Surgery
Patients who developed clinical symptoms of
hydrocephalus and those who did not show any
improvement within 6 weeks of starting anti-
tuberculosis treatment were subjected to a C.T.
Scan and a ventricular operational shunt was
performed if the diagnosis of hydrocephalus was
confirmed.
Bacteriological procedures
CSF specimens were examined by fluorescence
microscopy and cultured on multiple media namely
Lowenstein Jensen medium with and without
pyruvate, a selective 7H11 medium and selective
liquid Kirschner medium. Tests of sensitivity to
Streptomycin, Isoniazid, Rifampicin and
Ethambutol, were performed. All positive cultures
were subjected to identification tests.
Definitions of drug resistance
Streptomycin : A resistance ratio (RR) of 8 or
more on 1 culture, or 4 followed by 8 or more on a
repeat test.
Isoniazid : (a) Growth (defined as 20 colonies or
more) on 1 mg/L or a higher concentration, or
growth on 0.2 mg/L followed by the same result on
a repeat test.
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Rifampicin : Growth on 64 mg/L.
Ethambutol : Growth on 4 mg/L.
RESULTS
A total of 215 patients were admitted to the
study. On admission, 56% of the patients were aged
less than 3 years and 75% less than 5 years.
Approximately half the patients were males. Most
of the patients belonged to the lower socio-
economic group. Fifty percent of the patients hailed
from semi-urban and rural areas while the
remaining 50% came from urban areas.
The nutritional status of the patients was very
poor. Using growth standards set up by the Indian
Council of Medical Research, only 4% of the
patients were considered normal while 56% had
mild to moderate malnutrition and 40% had severe
malnutrition, based on deficit in weight for age:
There was no association between the nutritional
status and mortality. Only 5 patients had received
previous anti-tuberculosis chemotherapy for a
period ranging between 2 and 5 days. The time
interval between the onset of symptoms and
admission to hospital was 1-14 days in 53 (29%)
patients, 2 weeks to 4 weeks in 108 (58%) and 1-3
months in 24 (13%) patients. There was no
association between the duration of symptoms
before admission and the stage of the disease. On
admission, 4.5 (21%) patients were classified as
stage I, 160 (74%) as stage II and 10 (5%) as stage
III.
Tuberculin test with 1 T.U. was positive with an
induration of 10 mm or more in 73 (34%) patients;
a history of contact with a known case of pulmo-
nary tuberculosis was elicited in 137 (64%) patients
and an abnormal chest radiograph suggestive of tu-
berculosis was present in 111 (52%) patients. BCG
scar was present in 47 (22%) patients. CSF was
positive for tubercle bacilli either by smear, culture
or both in 101 (47%) patients. CSF smear was posi-
tive in 74 patients and in 14 patients, both smear
and culture were positive. Culture was, thus, posi-
tive in 88 patients (41%). Out of these, in 7 patients
(8%) the cultures were resistant to Streptomycin
alone, in 12 (14%) to INH alone, in 11 (12%) to
both Streptomycin and INH and in 2 (2%) to Strep-
tomycin, INH and Rifampicin.
Response to treatment
Of the 215 patients admitted to the study, in 10,
the prescribed treatment was modified, 1 patient
died of a non-tuberculous cause and 29 patients
were discharged against medical advice before
treatment was completed. Of these discharged
patients, 10 were reported to have died within 4
days of discharge. Since their general condition was
very poor at the time of discharge and the cause of
death was most likely to be tuberculous meningitis,
they were included in the analysis. Thus, the
analysis of response to treatment was based on 185
patients.
Table 1 gives the response to treatment in the
two regimens. Of the total 18.5 patients, 57 (3 1%)
died of tuberculous meningitis, 66 (36%) recovered
with neurological sequelae and the remaining 62
(34%) recovered fully without any sequelae. The
neurological sequelae were classified as severe.
moderate and mild.
Mild residual damage implied such sequelae as
hyperactivity, irritability, mild perceptual defects
and limited motor impairment such as facial paresis
or monoparesis.
Moderate residual damage included such defects
as hemiparesis, involuntary movements and
substantial mental impairment. Severe residual
damage included patients who either remained
Table 1. Response to treatment and status at 9 months according to treatment regimen
Regimen
No. in Died
analysis                                
No. %
Residual damage Complete
recovery
Total Severe  Modera te  Mi ld
No. %
No. %
2SEHR3Z3/7R2H2 89 26 29 31 35 4 21 6 32 36
2 SEHR2Z2/7R2H2 96 31 32 35 36 i 22 12 30 31
ALL 185 57 31 66 36 6 43 18 62 34
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unconscious or were conscious but were incapable
of independent existence.
Table 2 shows the response to treatment
according to stage. There was a clear association
between the stage on admission and the mortality,
the latter being highest in stage III patients (43%)
and lowest in stage 1 patients (10%) (statistically
significant with p = 0.002). There was no
association between the age of the patient and death
due to tuberculosis.
Table 3 shows the interval between admission
and death according to stage on admission. Of the
57 deaths, 29 (5%) occurred within the first month,
7 (12%) in the second month, 7 (12%) in the third
month, 13 (23%) between the fourth and sixth
months ard only one (2%) between the seventh and
ninth months of treatment. The last available CSF
result was biochemically abnormal in 50 of 57
patients who died and bacteriologically positive in
26. Table 4 shows that there was a clear association
between g resistance and response to treatment
(significant with p = 0.007).
Complications while on therapy
Hydrocephalus : In seventy four patients
hydrocephalus was suspected. Of these. C.T. Scan
could not be done in 6 patients due to various
reasons. On follow-up of these patients, 3 died
while the remaining 3 recovered with neurological
sequelae. The Scan was done in 68 patients and the
diagnosis was confirmed in all of them. Of these, in
38 patients, a ventricular-operational shunt was
performed while in the remaining 30, no surgery
was undertaken either because the parents were not
willing to subject their children to surgery or
because the patient died before the scheduled date.
Twenty five patients in the surgery group and 13 in
the non-surgery group died.
Blindness and optic disc changes
Five patients developed mild pallor of optic disc
while on treatment. In 4 of them, the changes
reverted to normal while in 1 patient it persisted till
Table 2. Response to treatment and status at 9 months according to stage on admission
Stage No. in Died Residual damage Complete
on analysis recovery
admission No. % Total Severe Modera te  Mi ld
No. %
No. %
I 41 4 10 7 17 0 3 4 30 73
II 137 50 36 56 41 5 37 14 31 23
III 7 3 (43)* 4 (43) 0 3 0 I (14)
ALL 185 57 31 66 36 5 43 18 62 34
* Figures in brackets indicate percentages based on a total fewer than 25 cases
Table 3. Interval between admission and death, according to stage of disease on admission
Stage
o f
disease
I
II
III
No. in Died of tuberculosis
analysis
Total Week of treatment Month of treatment
1 2 3 4 2 3 4 5 6 7-9
41 4 0 0 1 0 0 0 2 0 I 0
137 50 14 5 2 5 7 6 4 I 5 I
7 3 1 1 0 0 0 1 0 0 0 0
ALL 185 57 15 6 3 5 7 7 6 1 6 I
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the end of treatment.
Optic atrophy with blindness developed in 7
patients; 4 of these died and had the abnormal
finding till death, while the remaining 3 recovered
with moderate sequelae but the ocular changes
persisted till the end of therapy.
Discharge against  medical  advice before
completing treatment
Of the 215 patients started on treatment, 29
patients were discharged against medical advice; of
these, on follow up, 20 patients died (10 within 4
days of discharge) and the remaining 9 were alive.
Non-TB deaths
Only 1 patient (stage II) died of acute gastro-
enteritis in the third month of treatment.
Hepatic toxicity
This analysis is based on 205 patients after
excluding the 10 patients who had their treatment
modified. Table 5 shows that 10 patients (10%) in
regimen 1 and 3 patients (3%) in regimen II
developed clinical jaundice with abnormal liver
function test values (difference not statistically
significant). All except 1 patient developed jaundice
during the first 2 months of intensive therapy. Five
other patients developed only increase in the
enzyme levels with no clinical jaundice. Rifampicin
and Pyrazinamide were terminated in these patients
and the other drugs were continued.
DISCUSSION
Tuberculous meningitis is still the most serious
form of tuberculosis and carries a high mortality In
the earlier three studies conducted by the
Tuberculosis Research Centre1 , Rifampicin
containing regimens with and without
Pyrazinamide were used during the first 2 months
of intensive phase followed by Isoniazid and
Ethambutol daily for the next 10 months. The
mortality was very high in these studies and ranged
between 27 and 33%. It was felt that the drugs
given in the follow-up phase in these 3 studies were
not adequate. Hence, the regimens in the present
study were intensified by administering 5 drugs
namely Streptomycin, Isoniazid, Rifampicin.
Pyrazinamide and Ethambutol during the first 2
months followed by 2 bactericidal drugs namely
Isoniazid and Rifampicin for the next 7 months.
However, the results showed that despite using
intensive regimens, the mortality remained high
(31%). This indicates that in this form of
tuberculosis, early diagnosis and prompt
Table 4. Culture and sensitivity results related with response to treatment
Initial Culture/
Sensitivity
Total
no. in
analysis No.
Died Complete recovery
% No. %
Culture negative
Sensitive to S,H
Resistant to S,H or SH
* Of these 2 had resistance to R also
110 30 27 39 35
47 1 1 23 18 38
28* 16 57 5 18
Table 5. Occurrence of jaundice during treatment
Regimen No. of Patients who
patients developed jaundice Week of onset
admitted
No. % 1 2 3 4 5 6-8
2SEHR3Z3/7R2H2 103 10* 10 0 4 0 2 I 2
2SEHR2Z2/7R2H2 102 3 3 0 1 0 1 0 I
ALL 205 13 6 0 5 0 3 I 3
* Includes 1 patient who developed jaundice in the 3rd month
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treatment are more important than the drug
regimen. The results of the present study showed
that there was a direct relationship between the
stage of the disease on admission and the death rate,
the latter being highest in stage III patients and
lowest in stage I patients. Similar observations were
made by us in our first three studies, as well as by
other workers. The high mortality in the present
study could be due to various reasons like majority
of patients (79%) getting admission in the advanced
stage of the disease, inclusion in analysis of deaths
from day one of admission before the drugs could
start acting and also inclusion of the patients who
were discharged against medical advice in a critical
condition and died within 7 days of discharge. In
the present study, 29 of 57 (51%) deaths occurred
within 1 month of admission and 21 (37%) within 2
weeks.
In this study, Ethambutol was used only during
the first 2 months of intensive phase of therapy
mainly to prevent the emergence of further
resistance in patients with initial resistance to one or
more anti-tuberculosis drugs. Ethambutol has been
extensively used in the treatment of childhood
tuberculosis in India3-5. In all these studies the
dosage employed was 25 mg/kg for the first 2
months followed by 15 mg/kg and the reported
ocular toxicity was negligible. A study by Leibold6
suggests that, on a short term basis, it is safe to
prescribe as much as 45 mg/kg. In the present
study, Ethambutol was used only for 2 months in a
dosage of 20 mg/kg for 2 weeks followed by 15
mg/kg for the next 6 weeks. This dose and the short
duration are very unlikely to have produced ocular
changes. Also, optochiasmatic arachnoiditis
resulting in visual impartment or even blindness,
with or without associated hydrocephalus, is a
common complication of tuberculous meningitis.
All the 7 patients who developed optic atrophy with
blindness in the present study had moderate to
severe neurological damages and this is most likely
to be the cause of blindness.
In this study, clinical jaundice with abnormal
liver function test values was higher in those who
received Rifampcin thrice a week compared to
those who received the same drug twice a week.
This is in conformity with the findings of the other
studies undertaken in our Centre7.
The results of the present study show that despite
using intensive regimens, the mortality was very
high, specially in stages II and III patients, and it
was lowest in stage I patients. This emphasises the
need for early diagnosis and prompt treatment.
Since the results were similar in both the regimens
and the occurrence of jaundice was low in the group
where Rifampicin and Pyrazinamide were adminis-
tered twice a week, this regimen appears more suit-
able for the treatment of tuberculous meningitis.
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